Biofrontera AG

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, VRTX has a market cap of 96.3B. Regarding current trading prices, BFRA is priced at $2.67, while VRTX trades at $374.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VRTX's P/E ratio is -97.91. In terms of profitability, BFRA's ROE is -1.50%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, BFRA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check VRTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, REGN has a market cap of 60.5B. Regarding current trading prices, BFRA is priced at $2.67, while REGN trades at $569.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas REGN's P/E ratio is 14.04. In terms of profitability, BFRA's ROE is -1.50%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BFRA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check REGN's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ALNY has a market cap of 54.9B. Regarding current trading prices, BFRA is priced at $2.67, while ALNY trades at $418.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ALNY's P/E ratio is -168.92. In terms of profitability, BFRA's ROE is -1.50%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, BFRA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ALNY's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BFRA is priced at $2.67, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BFRA's ROE is -1.50%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BFRA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check SGEN's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ARGX has a market cap of 41.3B. Regarding current trading prices, BFRA is priced at $2.67, while ARGX trades at $674.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ARGX's P/E ratio is 34.31. In terms of profitability, BFRA's ROE is -1.50%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, BFRA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ARGX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, BNTX has a market cap of 26.7B. Regarding current trading prices, BFRA is priced at $2.67, while BNTX trades at $111.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BNTX's P/E ratio is -66.91. In terms of profitability, BFRA's ROE is -1.50%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, BFRA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check BNTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, SMMT has a market cap of 21.6B. Regarding current trading prices, BFRA is priced at $2.67, while SMMT trades at $29.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SMMT's P/E ratio is -85.68. In terms of profitability, BFRA's ROE is -1.50%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, BFRA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check SMMT's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RPRX has a market cap of 21.3B. Regarding current trading prices, BFRA is priced at $2.67, while RPRX trades at $37.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RPRX's P/E ratio is 15.47. In terms of profitability, BFRA's ROE is -1.50%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, BFRA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RPRX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BFRA is priced at $2.67, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BFRA's ROE is -1.50%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, BFRA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check BGNE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BFRA is priced at $2.67, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BFRA's ROE is -1.50%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, BFRA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check DNA-WT's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, INCY has a market cap of 15.2B. Regarding current trading prices, BFRA is priced at $2.67, while INCY trades at $77.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas INCY's P/E ratio is 18.37. In terms of profitability, BFRA's ROE is -1.50%, compared to INCY's ROE of +0.34%. Regarding short-term risk, BFRA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check INCY's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, UTHR has a market cap of 13.8B. Regarding current trading prices, BFRA is priced at $2.67, while UTHR trades at $304.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas UTHR's P/E ratio is 11.89. In terms of profitability, BFRA's ROE is -1.50%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BFRA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check UTHR's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, GMAB has a market cap of 13.6B. Regarding current trading prices, BFRA is priced at $2.67, while GMAB trades at $22.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas GMAB's P/E ratio is 13.00. In terms of profitability, BFRA's ROE is -1.50%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, BFRA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check GMAB's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BFRA is priced at $2.67, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BFRA's ROE is -1.50%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BFRA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check KRTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, BMRN has a market cap of 11.9B. Regarding current trading prices, BFRA is priced at $2.67, while BMRN trades at $61.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BMRN's P/E ratio is 22.94. In terms of profitability, BFRA's ROE is -1.50%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, BFRA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check BMRN's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ASND has a market cap of 11.3B. Regarding current trading prices, BFRA is priced at $2.67, while ASND trades at $186.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ASND's P/E ratio is -28.06. In terms of profitability, BFRA's ROE is -1.50%, compared to ASND's ROE of +1.91%. Regarding short-term risk, BFRA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ASND's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MRNA has a market cap of 10.6B. Regarding current trading prices, BFRA is priced at $2.67, while MRNA trades at $27.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MRNA's P/E ratio is -3.65. In terms of profitability, BFRA's ROE is -1.50%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, BFRA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MRNA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, EXEL has a market cap of 10.1B. Regarding current trading prices, BFRA is priced at $2.67, while EXEL trades at $37.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas EXEL's P/E ratio is 18.01. In terms of profitability, BFRA's ROE is -1.50%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, BFRA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check EXEL's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BFRA is priced at $2.67, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BFRA's ROE is -1.50%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RXDX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, BBIO has a market cap of 9.3B. Regarding current trading prices, BFRA is priced at $2.67, while BBIO trades at $49.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BBIO's P/E ratio is -13.82. In terms of profitability, BFRA's ROE is -1.50%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, BFRA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check BBIO's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, BFRA is priced at $2.67, while VRNA trades at $105.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VRNA's P/E ratio is -52.70. In terms of profitability, BFRA's ROE is -1.50%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, BFRA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check VRNA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BFRA is priced at $2.67, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BFRA's ROE is -1.50%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, BFRA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check IMGN's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, BFRA is priced at $2.67, while TECH trades at $54.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas TECH's P/E ratio is 65.83. In terms of profitability, BFRA's ROE is -1.50%, compared to TECH's ROE of +0.06%. Regarding short-term risk, BFRA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check TECH's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BFRA is priced at $2.67, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BFRA's ROE is -1.50%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, BFRA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check BPMC's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BFRA is priced at $2.67, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CERE's P/E ratio is -16.47. In terms of profitability, BFRA's ROE is -1.50%, compared to CERE's ROE of -0.43%. Regarding short-term risk, BFRA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CERE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, BFRA is priced at $2.67, while ROIV trades at $11.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ROIV's P/E ratio is -15.51. In terms of profitability, BFRA's ROE is -1.50%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, BFRA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ROIV's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, BFRA is priced at $2.67, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, BFRA's ROE is -1.50%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, BFRA is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ROIVW's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MDGL has a market cap of 7.5B. Regarding current trading prices, BFRA is priced at $2.67, while MDGL trades at $338.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MDGL's P/E ratio is -18.99. In terms of profitability, BFRA's ROE is -1.50%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, BFRA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MDGL's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, BFRA is priced at $2.67, while HALO trades at $60.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas HALO's P/E ratio is 16.17. In terms of profitability, BFRA's ROE is -1.50%, compared to HALO's ROE of +1.22%. Regarding short-term risk, BFRA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check HALO's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, BFRA is priced at $2.67, while CORT trades at $70.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CORT's P/E ratio is 62.90. In terms of profitability, BFRA's ROE is -1.50%, compared to CORT's ROE of +0.20%. Regarding short-term risk, BFRA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CORT's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RVMD has a market cap of 7.2B. Regarding current trading prices, BFRA is priced at $2.67, while RVMD trades at $38.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RVMD's P/E ratio is -9.57. In terms of profitability, BFRA's ROE is -1.50%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, BFRA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RVMD's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, BFRA is priced at $2.67, while IONS trades at $43.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IONS's P/E ratio is -24.46. In terms of profitability, BFRA's ROE is -1.50%, compared to IONS's ROE of -0.45%. Regarding short-term risk, BFRA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check IONS's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, JAZZ has a market cap of 6.8B. Regarding current trading prices, BFRA is priced at $2.67, while JAZZ trades at $113.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas JAZZ's P/E ratio is 15.38. In terms of profitability, BFRA's ROE is -1.50%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, BFRA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check JAZZ's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BFRA is priced at $2.67, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RETA's P/E ratio is -66.29. In terms of profitability, BFRA's ROE is -1.50%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BFRA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RETA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, BFRA is priced at $2.67, while RYTM trades at $88.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RYTM's P/E ratio is -30.97. In terms of profitability, BFRA's ROE is -1.50%, compared to RYTM's ROE of -1.78%. Regarding short-term risk, BFRA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RYTM's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, BFRA is priced at $2.67, while NUVL trades at $78.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas NUVL's P/E ratio is -17.79. In terms of profitability, BFRA's ROE is -1.50%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check NUVL's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BFRA is priced at $2.67, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BFRA's ROE is -1.50%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BFRA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ABCM's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BFRA is priced at $2.67, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BFRA's ROE is -1.50%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BFRA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ISEE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, BFRA is priced at $2.67, while ABVX trades at $70.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ABVX's P/E ratio is -20.98. In terms of profitability, BFRA's ROE is -1.50%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, BFRA is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ABVX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, BFRA is priced at $2.67, while AXSM trades at $103.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas AXSM's P/E ratio is -20.47. In terms of profitability, BFRA's ROE is -1.50%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, BFRA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check AXSM's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MRUS has a market cap of 5B. Regarding current trading prices, BFRA is priced at $2.67, while MRUS trades at $67.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MRUS's P/E ratio is -15.87. In terms of profitability, BFRA's ROE is -1.50%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, BFRA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MRUS's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, BFRA is priced at $2.67, while CRSP trades at $55.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CRSP's P/E ratio is -12.38. In terms of profitability, BFRA's ROE is -1.50%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, BFRA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CRSP's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RNA has a market cap of 4.6B. Regarding current trading prices, BFRA is priced at $2.67, while RNA trades at $38.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RNA's P/E ratio is -12.75. In terms of profitability, BFRA's ROE is -1.50%, compared to RNA's ROE of -0.27%. Regarding short-term risk, BFRA is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RNA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ADMA has a market cap of 4.5B. Regarding current trading prices, BFRA is priced at $2.67, while ADMA trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ADMA's P/E ratio is 22.57. In terms of profitability, BFRA's ROE is -1.50%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, BFRA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ADMA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, BFRA is priced at $2.67, while TGTX trades at $28.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas TGTX's P/E ratio is 74.74. In terms of profitability, BFRA's ROE is -1.50%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, BFRA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check TGTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BFRA is priced at $2.67, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BFRA's ROE is -1.50%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, BFRA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ALPN's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, BFRA is priced at $2.67, while ALKS trades at $26.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ALKS's P/E ratio is 12.85. In terms of profitability, BFRA's ROE is -1.50%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, BFRA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ALKS's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ZLAB has a market cap of 4.4B. Regarding current trading prices, BFRA is priced at $2.67, while ZLAB trades at $39.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ZLAB's P/E ratio is -15.80. In terms of profitability, BFRA's ROE is -1.50%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, BFRA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ZLAB's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, BFRA is priced at $2.67, while PCVX trades at $33.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PCVX's P/E ratio is -8.45. In terms of profitability, BFRA's ROE is -1.50%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, BFRA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check PCVX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CYTK has a market cap of 4.3B. Regarding current trading prices, BFRA is priced at $2.67, while CYTK trades at $36.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CYTK's P/E ratio is -6.84. In terms of profitability, BFRA's ROE is -1.50%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, BFRA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CYTK's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, SLNO has a market cap of 4.3B. Regarding current trading prices, BFRA is priced at $2.67, while SLNO trades at $81.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SLNO's P/E ratio is -17.22. In terms of profitability, BFRA's ROE is -1.50%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, BFRA is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check SLNO's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BFRA is priced at $2.67, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas OPT's P/E ratio is -1.52. In terms of profitability, BFRA's ROE is -1.50%, compared to OPT's ROE of +2.60%. Regarding short-term risk, BFRA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check OPT's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, TLX has a market cap of 4.1B. Regarding current trading prices, BFRA is priced at $2.67, while TLX trades at $12.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas TLX's P/E ratio is 136.22. In terms of profitability, BFRA's ROE is -1.50%, compared to TLX's ROE of +0.06%. Regarding short-term risk, BFRA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check TLX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BFRA is priced at $2.67, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BFRA's ROE is -1.50%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BFRA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MRTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, BFRA is priced at $2.67, while PTCT trades at $51.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PTCT's P/E ratio is 7.85. In terms of profitability, BFRA's ROE is -1.50%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, BFRA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check PTCT's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, BFRA is priced at $2.67, while ACLX trades at $72.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ACLX's P/E ratio is -24.09. In terms of profitability, BFRA's ROE is -1.50%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, BFRA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ACLX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, KRYS has a market cap of 4B. Regarding current trading prices, BFRA is priced at $2.67, while KRYS trades at $137.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KRYS's P/E ratio is 38.26. In terms of profitability, BFRA's ROE is -1.50%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, BFRA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check KRYS's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, BFRA is priced at $2.67, while ACAD trades at $23.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ACAD's P/E ratio is 17.26. In terms of profitability, BFRA's ROE is -1.50%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, BFRA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ACAD's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, AKRO has a market cap of 4B. Regarding current trading prices, BFRA is priced at $2.67, while AKRO trades at $49.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas AKRO's P/E ratio is -13.15. In terms of profitability, BFRA's ROE is -1.50%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, BFRA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check AKRO's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, AAPG has a market cap of 3.9B. Regarding current trading prices, BFRA is priced at $2.67, while AAPG trades at $42.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas AAPG's P/E ratio is -57.28. In terms of profitability, BFRA's ROE is -1.50%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, BFRA is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check AAPG's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, BFRA is priced at $2.67, while VKTX trades at $34.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas VKTX's P/E ratio is -22.10. In terms of profitability, BFRA's ROE is -1.50%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, BFRA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check VKTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BFRA is priced at $2.67, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BFRA's ROE is -1.50%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BFRA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RYZB's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BFRA is priced at $2.67, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BFRA's ROE is -1.50%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BFRA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CBAY's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BFRA is priced at $2.67, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BFRA's ROE is -1.50%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, BFRA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check SWTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, BFRA is priced at $2.67, while LEGN trades at $38.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas LEGN's P/E ratio is -32.84. In terms of profitability, BFRA's ROE is -1.50%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, BFRA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check LEGN's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, BFRA is priced at $2.67, while SRRK trades at $36.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas SRRK's P/E ratio is -14.50. In terms of profitability, BFRA's ROE is -1.50%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, BFRA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check SRRK's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MTSR has a market cap of 3.5B. Regarding current trading prices, BFRA is priced at $2.67, while MTSR trades at $33.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MTSR's P/E ratio is -11.50. In terms of profitability, BFRA's ROE is -1.50%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, BFRA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MTSR's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, BFRA is priced at $2.67, while MLTX trades at $53.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MLTX's P/E ratio is -23.22. In terms of profitability, BFRA's ROE is -1.50%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MLTX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, BFRA is priced at $2.67, while PTGX trades at $53.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PTGX's P/E ratio is 69.10. In terms of profitability, BFRA's ROE is -1.50%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, BFRA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check PTGX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, APLS has a market cap of 3.1B. Regarding current trading prices, BFRA is priced at $2.67, while APLS trades at $24.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas APLS's P/E ratio is -13.22. In terms of profitability, BFRA's ROE is -1.50%, compared to APLS's ROE of -1.16%. Regarding short-term risk, BFRA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check APLS's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, BFRA is priced at $2.67, while KYMR trades at $42.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KYMR's P/E ratio is -13.82. In terms of profitability, BFRA's ROE is -1.50%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, BFRA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check KYMR's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, BFRA is priced at $2.67, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MORF's P/E ratio is -14.88. In terms of profitability, BFRA's ROE is -1.50%, compared to MORF's ROE of -0.22%. Regarding short-term risk, BFRA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MORF's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, BFRA is priced at $2.67, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MOR's P/E ratio is -12.64. In terms of profitability, BFRA's ROE is -1.50%, compared to MOR's ROE of -1.84%. Regarding short-term risk, BFRA is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MOR's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, BFRA is priced at $2.67, while IMVT trades at $16.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IMVT's P/E ratio is -6.05. In terms of profitability, BFRA's ROE is -1.50%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, BFRA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check IMVT's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, BFRA is priced at $2.67, while CRNX trades at $29.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CRNX's P/E ratio is -7.69. In terms of profitability, BFRA's ROE is -1.50%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, BFRA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CRNX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, BFRA is priced at $2.67, while RARE trades at $28.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RARE's P/E ratio is -4.96. In terms of profitability, BFRA's ROE is -1.50%, compared to RARE's ROE of -1.86%. Regarding short-term risk, BFRA is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RARE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CPRX has a market cap of 2.7B. Regarding current trading prices, BFRA is priced at $2.67, while CPRX trades at $22.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CPRX's P/E ratio is 13.80. In terms of profitability, BFRA's ROE is -1.50%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, BFRA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CPRX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, BFRA is priced at $2.67, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KDNY's P/E ratio is -12.47. In terms of profitability, BFRA's ROE is -1.50%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, BFRA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check KDNY's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, XENE has a market cap of 2.6B. Regarding current trading prices, BFRA is priced at $2.67, while XENE trades at $34.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas XENE's P/E ratio is -10.68. In terms of profitability, BFRA's ROE is -1.50%, compared to XENE's ROE of -0.32%. Regarding short-term risk, BFRA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check XENE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, BFRA is priced at $2.67, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MYOV's P/E ratio is -14.05. In terms of profitability, BFRA's ROE is -1.50%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, BFRA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MYOV's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, BFRA is priced at $2.67, while LGND trades at $135.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas LGND's P/E ratio is -18.54. In terms of profitability, BFRA's ROE is -1.50%, compared to LGND's ROE of -0.16%. Regarding short-term risk, BFRA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check LGND's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, BFRA is priced at $2.67, while MIRM trades at $51.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas MIRM's P/E ratio is -32.20. In terms of profitability, BFRA's ROE is -1.50%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, BFRA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check MIRM's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, BFRA is priced at $2.67, while KNSA trades at $33.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas KNSA's P/E ratio is 661.40. In terms of profitability, BFRA's ROE is -1.50%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, BFRA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check KNSA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, BFRA is priced at $2.67, while NAMS trades at $21.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas NAMS's P/E ratio is -11.81. In terms of profitability, BFRA's ROE is -1.50%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, BFRA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check NAMS's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, BFRA is priced at $2.67, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas PRVB's P/E ratio is -16.43. In terms of profitability, BFRA's ROE is -1.50%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, BFRA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check PRVB's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, RXRX has a market cap of 2.4B. Regarding current trading prices, BFRA is priced at $2.67, while RXRX trades at $5.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas RXRX's P/E ratio is -3.07. In terms of profitability, BFRA's ROE is -1.50%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, BFRA is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check RXRX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, BFRA is priced at $2.67, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas LBPH's P/E ratio is -26.66. In terms of profitability, BFRA's ROE is -1.50%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, BFRA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check LBPH's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, BFRA is priced at $2.67, while NAMSW trades at $10.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas NAMSW's P/E ratio is N/A. In terms of profitability, BFRA's ROE is -1.50%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, BFRA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check NAMSW's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, BFRA is priced at $2.67, while CNTA trades at $17.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CNTA's P/E ratio is -9.21. In terms of profitability, BFRA's ROE is -1.50%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, BFRA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CNTA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, BFRA is priced at $2.67, while APGE trades at $38.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas APGE's P/E ratio is -10.77. In terms of profitability, BFRA's ROE is -1.50%, compared to APGE's ROE of -0.19%. Regarding short-term risk, BFRA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check APGE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, ARWR has a market cap of 2.3B. Regarding current trading prices, BFRA is priced at $2.67, while ARWR trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas ARWR's P/E ratio is -13.28. In terms of profitability, BFRA's ROE is -1.50%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, BFRA is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check ARWR's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, BFRA is priced at $2.67, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas DICE's P/E ratio is -21.91. In terms of profitability, BFRA's ROE is -1.50%, compared to DICE's ROE of +0.56%. Regarding short-term risk, BFRA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check DICE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, BFRA is priced at $2.67, while IBRX trades at $2.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IBRX's P/E ratio is -4.16. In terms of profitability, BFRA's ROE is -1.50%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, BFRA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check IBRX's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, BFRA is priced at $2.67, while GLPG trades at $32.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas GLPG's P/E ratio is -6.46. In terms of profitability, BFRA's ROE is -1.50%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, BFRA is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check GLPG's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, BLTE has a market cap of 2.2B. Regarding current trading prices, BFRA is priced at $2.67, while BLTE trades at $66.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas BLTE's P/E ratio is -46.05. In terms of profitability, BFRA's ROE is -1.50%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, BFRA is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check BLTE's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, FOLD has a market cap of 2.2B. Regarding current trading prices, BFRA is priced at $2.67, while FOLD trades at $6.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas FOLD's P/E ratio is -58.25. In terms of profitability, BFRA's ROE is -1.50%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, BFRA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check FOLD's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, BFRA is priced at $2.67, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas CALT's P/E ratio is -22.73. In terms of profitability, BFRA's ROE is -1.50%, compared to CALT's ROE of -1.67%. Regarding short-term risk, BFRA is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check CALT's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, IDYA has a market cap of 2.1B. Regarding current trading prices, BFRA is priced at $2.67, while IDYA trades at $24.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IDYA's P/E ratio is -6.61. In terms of profitability, BFRA's ROE is -1.50%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, BFRA is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check IDYA's competition here

BFRA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BFRA stands at 0. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, BFRA is priced at $2.67, while IRON trades at $60.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BFRA currently has a P/E ratio of -4.35, whereas IRON's P/E ratio is -15.40. In terms of profitability, BFRA's ROE is -1.50%, compared to IRON's ROE of -0.23%. Regarding short-term risk, BFRA is more volatile compared to IRON. This indicates potentially higher risk in terms of short-term price fluctuations for BFRA.Check IRON's competition here